Chemistry:Tazobactam
From HandWiki
Short description: Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| License data | |
| Pregnancy category |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H12N4O5S |
| Molar mass | 300.29 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tazobactam is a pharmaceutical drug that inhibits the action of bacterial β-lactamases, especially those belonging to the SHV-1 and TEM groups. It is commonly used as its sodium salt, tazobactam sodium.
Tazobactam is combined with the extended spectrum β-lactam antibiotic piperacillin in the drug piperacillin/tazobactam, used in infections due to Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin.[1]
Tazobactam was patented in 1982 and came into medical use in 1992.[2]
See also
References
- ↑ "Class A beta-lactamases--enzyme-inhibitor interactions and resistance". Pharmacology & Therapeutics 83 (2): 141–151. August 1999. doi:10.1016/S0163-7258(99)00027-3. PMID 10511459.
- ↑ (in en) Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 490. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA490.
 |  |
